Dr. Catherine Harrell, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 802
Licensed in Texas since 2012, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Texas Medical School at Houston
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
TX license P2057 (first issued 2012; active) · TX license BP20039384 -
Internal Medicine Physician
TX license BP20039384
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Dermatology Specialists of Fort Worth PLLC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 802
- Services billed
- 4,510
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,549 | 232 |
| Established patient office or other outpatient visit, 20-29 minutes | 924 | 620 |
| Destruction of precancer skin growth, 1 growth | 417 | 305 |
| Biopsy of related skin growth, first growth | 301 | 232 |
| Destruction of skin growth, 1-14 growths | 294 | 240 |
| Biopsy of related skin growth, each additional growth | 112 | 68 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 71 | 54 |
| New patient office or other outpatient visit, 30-44 minutes | 70 | 70 |
| Established patient office or other outpatient visit, 30-39 minutes | 63 | 50 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 46 | 45 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 103 payments worth $2,763 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $538 |
|---|---|
| Genzyme Corporation | $484 |
| Galderma Laboratories, L.P. | $256 |
| Leo Pharma Inc. | $200 |
| Incyte Corporation | $184 |
| Janssen Biotech, Inc. | $170 |
| AbbVie Inc. | $165 |
| Amgen Inc. | $141 |
| Food and Beverage | $2,763 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.